Expanding Reach with New Global Partnerships
PharmaResearch has taken a significant step in strengthening its distribution capabilities across the European market. By forming a strategic partnership with VIVACY, a renowned medical aesthetics corporation, they aim to enhance the availability of their innovative medical device brand, Rejuran, throughout Europe.
Strategic Collaboration with VIVACY
VIVACY, based in France, boasts a strong market presence and expertise in aesthetic medicine, making this collaboration highly beneficial. This partnership will leverage both companies’ strengths—PharmaResearch's advanced regenerative medicine solutions and VIVACY's comprehensive distribution network that spans several key markets across Europe.
VIVACY's Market Strength
Headquartered in France, VIVACY is prominent in the realm of medical aesthetics, offering superior quality products. Their vast network ensures efficient reaching of various European markets, establishing a solid foundation for the launch of Rejuran. This collaboration not only seeks to elevate Rejuran's visibility but also aims to enhance consumer access to cutting-edge regenerative treatments.
Details of the Agreement
This strategic distribution agreement is valued at approximately EUR 54.5 million over the next five years and encompasses a reach into 22 European countries, covering critical markets. This includes countries like the United Kingdom, Germany, France, Italy, and Spain—each known for their evolving and expansive cosmetic sectors.
Future Distribution Plans
PharmaResearch plans to initiate product distribution within critical European markets soon. They aim for a gradual rollout strategy that will expand their footprint in adjacent markets, providing consumers with timely access to their innovative solutions.
Company Perspectives
Jihoon Sohn, CEO of PharmaResearch, expressed confidence in the partnership's potential, noting that Rejuran is currently the only Polynucleotide-based medical device approved under the EU Medical Device Regulation (MDR). This distinction provides an excellent opportunity to fortify Rejuran's position in the global market.
Enhancing Global Visibility
In his statement, Sohn emphasized their commitment to elevating Rejuran's global presence as a premier skin booster in the international medical aesthetics arena. This partnership represents a major advancement towards achieving that goal.
Commitment to Quality and Innovation
The partnership was also praised by Bertrand, the CEO of VIVACY, who recognized the quality and efficacy of Rejuran's premium brand positioning. He highlighted the vital blend of VIVACY's scientific reputation with PharmaResearch's innovative technology as a key factor for success in entering the European market.
About PharmaResearch
PharmaResearch is recognized as a pioneering biopharmaceutical firm committed to enhancing the quality of life through innovative regenerative medicine. Their extensive portfolio includes pharmaceuticals, medical devices, cosmetics, and supplements. The company focuses on leveraging their unique core ingredients, protected by a collection of patents, to deliver effective health solutions.
Conclusion
This strategic partnership not only broadens PharmaResearch’s reach in Europe but also signifies a crucial development in the medical aesthetics industry, setting the stage for innovative treatment options like Rejuran to become more accessible across the continent.
Frequently Asked Questions
What is the focus of PharmaResearch?
PharmaResearch is dedicated to advancing regenerative medicine to improve the quality of life through innovative treatments and products.
What product is being distributed in Europe?
The product being distributed is Rejuran, a Polynucleotide-based medical device aimed at enhancing skin aesthetics.
How large is the distribution partnership?
The partnership with VIVACY covers an agreement valued at approximately EUR 54.5 million over five years, reaching 22 countries.
What distinguishes Rejuran in the market?
Rejuran is the only Polynucleotide-based medical device approved under the EU Medical Device Regulation, marking its uniqueness in the market.
When is PharmaResearch planning to launch in Europe?
PharmaResearch intends to start distribution in key European countries soon, with phased rollouts planned for broader market access.
